Paeds Cases · rheumatology-musculoskeletal-and-sports
Assess a child with persistent bone pain for malignancy red flags — long case
Long-case structured assessment of a child with persistent, progressive, night-waking bone pain: running the red-flag screen, choosing the same-day basic investigations, reading the radiographic signature of osteosarcoma, applying the never-biopsy-outside-a-specialist-centre rule, and framing the prognosis and disposition for the family.
On this page & tools
Target exams
Candidate brief
You have fifteen minutes to assess and reason through this long case as the general paediatric registrar receiving the referral. Take a focused history of the pain pattern and the systemic search, examine to localise the tenderness and the mass, interpret the radiograph, identify the diagnosis and the red flags that should have triggered earlier investigation, and lay out the immediate management, the correct referral pathway, and the prognosis you would frame for the family. [5] [8]
You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References4Show ledgerHide ledger
- [5]Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer, 2009.PMID 19197972
- [7]Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteograsarcoma Study) cohort. European Journal of Cancer, 2019.PMID 30685685
- [8]George A, Grimer R. Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier? Annals of the Royal College of Surgeons of England, 2012.PMID 22613305
- [10]Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology, 2016.PMID 27569442